These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 26662931)

  • 21. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
    Lee HJ; Han E; Kim H
    Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry.
    Ruyssen-Witrand A; Boudali Y; Pane I; Cantagrel A; Thevenot P; Soubrier M; Morel J; Houvenagel E; Saraux A; Basch A; Truchetet ME; Marotte H; Dernis E; Claudepierre P; Flipo RM; Gottenberg JE; Ravaud P; Mariette X; Seror R
    Joint Bone Spine; 2022 May; 89(3):105310. PubMed ID: 34838991
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 25. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
    Schabert VF; Watson C; Gandra SR; Goodman S; Fox KM; Harrison DJ
    J Med Econ; 2012; 15(2):264-75. PubMed ID: 22115327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosimilars in rheumatology.
    Araújo FC; Gonçalves J; Fonseca JE
    Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biosimilars for the treatment of psoriatic arthritis.
    Cantini F; Benucci M; Li Gobbi F; Franchi G; Niccoli L
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1195-1203. PubMed ID: 31625769
    [No Abstract]   [Full Text] [Related]  

  • 28. Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching.
    Cohen HP; Bodenmueller W
    BioDrugs; 2024 May; 38(3):331-339. PubMed ID: 38520607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System.
    Jourdain H; Hoisnard L; Sbidian E; Zureik M
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38453213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia.
    Dormuth CR; Fisher A; Carney G
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):796-802. PubMed ID: 31914214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
    Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
    J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway.
    Goll GL; Kvien TK
    Expert Opin Biol Ther; 2023; 23(12):1203-1209. PubMed ID: 37874218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA approves biosimilar version of infliximab.
    Traynor K
    Am J Health Syst Pharm; 2016 May; 73(10):604-6. PubMed ID: 27147206
    [No Abstract]   [Full Text] [Related]  

  • 34. Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.
    Cárdenas M; de la Fuente S; Font P; Castro-Villegas M; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérez J; Escudero-Contreras A; Casado M; Del Prado J; Collantes-Estévez E
    Rheumatol Int; 2016 Feb; 36(2):231-41. PubMed ID: 26494567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.
    Kim SC; Sarpatwari A; Landon JE; Desai RJ
    Arthritis Rheumatol; 2020 Jun; 72(6):1036-1038. PubMed ID: 31943866
    [No Abstract]   [Full Text] [Related]  

  • 37. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U; Hong S; Oh C; Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population.
    Fisher MD; Watson C; Fox KM; Chen YW; Gandra SR
    Curr Med Res Opin; 2013 May; 29(5):561-8. PubMed ID: 23489410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilar infliximab: an expert view.
    Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
    G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.
    Dean EB; Johnson P; Bond AM
    JAMA Netw Open; 2021 Jan; 4(1):e2034776. PubMed ID: 33502485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.